Stryker will pay $80 million, $40 million under the False Claims Act, and subsidiary OtisMed, will be excluded from doing business with Medicare, Medicaid and other government health programs for 20 years, in exchange for the Deparment of Justice not criminally prosecuting Stryker for distributing knee surgery cutting guides after they were rejected by the FDA.

FCA | Joel Hesch, Stryker, OtisMed, FDA